The EMSY gene encodes a protein that interacts with Brca2 and is amplifi ed in some sporadic cases of human breast cancer. To examine whether overexpression of EMSY would mimic the chromosome instability phenotype that is associated with the loss of Brca2 function, we constructed a lentiviral vector (Lenti-EMSY/GFP) that encodes a truncated form of the Emsy protein, including its Brca2-interacting domain, and green fl uorescent protein (GFP) and used it to transduce human telomerase-immortalized human breast epithelial ( 
The EMSY gene ( 1 ) encodes a protein whose amino-terminal region binds to the protein domain encoded by the third exon of the BRCA2 gene, which is deleted from the germline DNA of familial breast cancer kindreds ( 2 ) . The aminoterminal region of the Emsy protein also contains separate domains that bind to the HP1 β and BS69 proteins ( Fig. 1, A ) , which suggests that Emsy may also play a role in chromatin remodeling ( 1 ) . In irradiated cells, Emsy has been found to colocalize with γ -histone 2AX in response to DNA damage ( 1 ) . BRCA2 gene mutations are not seen in sporadic breast cancer, but the EMSY gene is amplifi ed in 13% of these cancers ( 1 ) . In primary breast cancer samples and breast cancer cell lines, amplifi cation of 11q13.5, the chromosomal region that contains the EMSY gene, is specifi cally correlated with an increase in levels of EMSY messenger RNA (mRNA) ( 3 ) . Taken together, these fi ndings have led to the suggestion that overexpression of the EMSY gene might be an alternative mechanism for suppressing Brca2 activity, which could lead to the emergence of malignant breast cell populations ( 4 -6 ) .
BRCA2-null cells exhibit a chromosome instability phenotype that is characterized by the accumulation of structural chromosomal abnormalities in response to exposure to mitomycin C ( 7 -9 ) . In humans, loss of heterozygosity at the BRCA2 locus is associated with genomic instability early in breast cancer development and antedates the appearance of carcinoma in situ ( 10 ) . We therefore hypothesized that forced overexpression of EMSY might cause a chromosome instability phenotype in human breast epithelial cells similar to that typical of BRCA2-null cells.
To test this hypothesis, we isolated a 810-bp 5 ′ fragment from the EMSY complementary DNA (cDNA) that encodes the Brca2-interacting domain as well as the HP1 β -and BS69-binding domains and inserted this fragment into a lentiviral vector that already contained an internal ribosomal entry site element and the cDNA for enhanced green fl uorescent protein (eGFP) ( 11 ) ( Fig. 1, A ) . We then used this vector or the control lentiviral vector expressing GFP only (Lenti-GFP) to infect log-phase 184-hTert cells, a telomerase-immortalized line of human breast epithelial cells ( 12 ) generously supplied by S. Dunn, Department of Pediatrics and Experimental Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Two days later, we used a fl uorescence-activated cell sorter to select EMSY/GFP-and control GFPtransduced cells that displayed high levels of green fl uorescence ( Fig. 1, B ) , and the selected cells were cultured further for up to fi ve passages. By passage 5, the EMSY/GFP-transduced cells from three independent transduction experiments expressed 68-to 300-fold higher levels of EMSY mRNA that contained sequences from the 5 ′ end of the EMSY gene compared with control GFPtransduced cells ( Fig. 1, C ) . In the same EMSY/GFP-transduced cells, expression of the endogenous EMSY gene (i.e., EMSY mRNA that contained sequences from the 3 ′ end of the gene) ( Fig. 1, C ) or genes encoding Brca1, Brca2, p21, or p53 (data not shown) was not different from the expression of any of these genes in the GFP-transduced control cells. The level of 5 ′ EMSY transcripts in the transduced cells continued to increase with further cell passage (data not shown), suggesting overgrowth of the cultures by cells that expressed the highest levels of the EMSY transgene.
The parental 184-hTert cells had a nearly diploid karyotype (48, XX, +20, +20) and were chromosomally stable. By contrast, in three separate experiments, cells that overexpressed mRNA from the EMSY transgene rapidly accumulated structural chromosomal abnormalities. These abnormalities included deletions, translocations, marker chromosomes, chromosome fragments, and dicentric chromosomes ( Fig. 2, A ) , none of which were seen in metaphases from control GFP-transduced cells. For example, at passage 5 after transduction, 39 (26%) of 150 metaphases of EMSY/GFPtransduced cells contained at least one structural chromosomal abnormality compared with 19 (13%) of 150 metaphases from the GFP-transduced cells ( P = .003, chi-square test; 50 metaphase cells of each type examined in each of three experiments) ( Table 1 ). The highest frequency of cells with structural chromosomal abnormalities (32%) was seen in cells that expressed the highest levels of the EMSY transgene (Experiment 1).
Conversely, cells that expressed lower levels of the EMSY transgene contained fewer cells with structural chromosomal abnormalities (22% in Experiment 2 and 24% in Experiment 3). By passage 10 after transduction, the frequency of structural chromosomal abnormalities in the EMSY-overexpressing cells had increased further to 44%, 48%, and 34% in Experiments 1, 2, and 3, respectively, but remained low (18%, 12%, and 14%, respectively) in the corresponding control cells ( P <.001, chi-square test) ( Table 1 ) . We also analyzed EMSY/GFP-transduced (BS) binding domains was amplifi ed by PCR using oligonucleotide primers EMSY-1 -810-F (5 ′ -GGCGCGCCCCACCATGCCTGTTGTGTGGCC-3 ′ ; forward primer) and EMSY-1 -810-R (5 ′ -TTAATTAATGTCTGTGTTGATGGTT TAG-3 ′ ; reverse primer) and cloned into the PCR-2.1-Topo vector (Invitrogen, Burlington, Ontario, Canada). The cloned insert was isolated by digestion of the plasmid with Asc I and Pac I, purifi ed, and reinserted into the multiple cloning site (MCS) of the KA391 lentiviral vector. Vesicular stomatitis virus envelope-pseudotyped Lenti-EMSY/GFP or Lenti-GFP virus was produced in 293T cells, concentrated, and titered on HeLa cells as previously described ( 11 ) . ( B ) Fluorescence-activated cell sorter analysis profi les of parental 184-hTert cells (left panel), EMSY/GFP-transduced cells analyzed 2 days after transduction (middle panel), and control GFP-transduced cells analyzed 2 days after transduction (right panel). Approximately 10 5 log phase 184-hTert cells were cultured overnight in six-well plates in regular growth medium (50% Dulbecco's minimal essential medium with 1000 mg/L glucose and 50% Ham's F12 medium plus 2.38 g/L HEPES, 10 ng/L epidermal growth factor, 0.25 ng/mL insulin, 10 − 6 M hydrocortisone, 1 μ g/L transferrin, 2.6 ng/mL sodium selenite, 30 U/mL prolactin, 1 n M estradiol, 2.5 mg/mL isoproterenol, and 400 μ g/mL G418), and the next day, the cells were incubated for 4 hours with 500 μ L of medium containing 1.2 × 10 7 infectious units of Lenti-EMSY/GFP or Lenti-GFP virus, after which the medium was replaced with the normal growth medium for another 48 hours. Cells displaying the top 20% of fl uorescence levels (arrows) were isolated using a FACSVantage fl ow cytometry system (Becton Dickinson, City, CA) and further propagated in six-well plates. PI = propidium iodide, FSC = forward light scattering characteristics. ( C ) Transcript levels in passage 5 EMSY/GFP-and control GFP-transduced 184-hTert cells from all three transduction experiments were quantifi ed by real-time PCR (7500 Sequence Detection System, Applied Biosystems) using TaqMan probes and primers designed to specifi cally detect transcripts containing the 5 ′ or 3 ′ ends of EMSY. This was done to allow the full-length (endogenous) EMSY transcripts (which contained both 5 ′ and 3 ′ sequences) to be measured separately from the more prevalent transgenederived transcripts (which contained 5 ′ sequences but not 3 ′ sequences). EMSY transcript levels in each sample were normalized relative to an internal reference control and then compared to similarly normalized values measured in GFPtransduced cells. Values shown are the mean fold difference (± standard deviation) between values from EMSY/GFP-versus control GFP-transduced cells. ( D ) Northern blot analysis of EMSY RNA expression in EMSY/GFP-transduced (+) or GFP-transduced ( − ) 184-hTert cells from three separate experiments (lanes 1 -6). RNA was extracted at passage 2 after transduction, and 10 μ g was size fractionated on an agarose gel. Four clones of EMSY/GFP-transduced cells from the fi rst experiment were isolated at passage 3 and grown for fi ve additional passages (lanes 7 -10). EMSY mRNA levels were detected by using a 32 P-labeled probe specifi c for the human EMSY cDNA.
and control GFP-transduced cells in interphase for chromosome copy number changes at four loci using a commercially available kit (Breast Aneusomy MultiColor Probe Set; Vysis, Downers Grove, IL). This analysis showed that the frequency of aneuploid cells in the EMSYoverexpressing cells was statistically signifi cantly higher than that in the control GFP-overexpressing cells at passage 5 (76 aneuploid cells per 300 cells analyzed versus 33 aneuploid cells per 300 cells analyzed, P <.001, chi-square test) and at passage 10 (88 aneuploid cells per 300 cells analyzed versus 34 aneuploid cells per 300 cells analyzed, P <.001, chi-square test). Examples of these aneuploid cells are shown in Fig. 2C . We also isolated four clones from EMSY/ GFP-transduced cells at passage 3 from Experiment 1 ( Fig. 1, D , lanes 7 -10) , confi rmed their separate origins by integration site analysis of the EMSY transgene (data not shown), and then analyzed 15 metaphases from each clone using 24-color fl uorescence in situ hybridization. All four clones contained cells that had a variety of complex structural as well as numerical chromosomal aberrations, i.e., karyotypes ranging from near tetraploid to near diploid, with multiple deletions and translocations. Examples of these abnormalities in three of the clones are shown in Fig. 2, D . EMSY/GFP-transduced cell populations had a statistically signifi cantly higher frequency of aneuploid or polyploid cells than GFP-transduced cell populations at passage 10 ( P = .002, chi-square test) ( Table 1 ) but not at passage 5 ( P >.05, chi-square test). Taken together, these fi ndings indicate that cells that express elevated levels of the 5 ′ end of EMSY display a genomic instability phenotype that is consistent, specifi c, stable, and probably dependent on the level of EMSY transgene mRNA expression.
A hallmark of BRCA2-defi cient cells is their increased sensitivity to DNA crosslinking agents such as mitomycin C, which cause the cells to accumulate structural chromosomal abnormalities because of their decreased ability to repair double-stranded breaks in their Thus, overexpression of a 5 ′ fragment of EMSY induces a chromosome instability phenotype in human breast epithelial cells that is similar to that of BRCA2-defi cient cells. Although this observation has yet to be extended to other cell lines, the data provide new experimental evidence to support the hypothesis that elevated levels of Emsy may play a role in sporadic breast oncogenesis by deregulating genomic stability. There are several potential mechanisms by which such a phenotype might be produced, including effects of Emsy overexpression on the fi delity of DNA replication and/or repair of double-stranded breaks through interference with the normal role of Brca2 and its ability to bind Rad51 ( 13 ) . EMSYoverexpressing cancers, like those with a BRCA2-null genotype, might then be expected to have an enhanced sensitivity to agents (other than mitomycin C) that selectively damage BRCA2-null cells ( 14 ) . Alternatively, overexpression of the truncated EMSY cDNA used in this study might produce a BRCA-null phenotype through a dominant-negative mechanism. Future experiments in which the full-length Emsy protein is overexpressed will be important to resolve these possibilities. It will also be of interest to determine whether the truncated form of Emsy expressed in the present studies affects the half-life or activity of Brca2, or its other binding partners. It should be noted that the levels of EMSY expression obtained in the experimental model described here are more than 10-fold higher than those documented in naturally arising tumors that take years to develop ( 3 ) , but also allow a pronounced genomic instability phenotype to be produced within a few weeks. This model should thus provide a useful system for future delineation of the mechanisms by which the effects of more subtle changes in EMSY overexpression may be mediated. † P values shown were calculated using a chi-square test. P >.05 was considered non-statistically signifi cant.
